Key clinical point: Serlopitant provides clinically meaningful improvement in psoriatic itch.
Major finding: A 4-point or greater reduction on the Worst Itch Numeric Rating Scale was achieved in 33.9% of psoriasis patients on serlopitant at 5 mg once daily and 21.1% of placebo-treated controls.
Study details: This phase 2, double-blind, 8-week, placebo-controlled randomized trial included 204 adults with plaque psoriasis study.
Disclosures: The study was funded by Menlo Therapeutics. The presenter reported receiving research funding from and/or serving as a consultant to or advisory board member for roughly two dozen pharmaceutical companies.
Pariser DM. EADV Congress 2019.